Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Operating Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,513 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 134,513 · Balance 134,513 F1: These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2036-09-01 | Direct | 265,487 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 265,487 · Balance 265,487 F2: The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.
F2: The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 21:21 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 265,487 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0002148701-26-000008 · form4-09012026_090941.xml · derivative · entry 2 Abu-Absi Susan · CIK 0002148701 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,487 Underlying: Common Stock · 265,487 shares Expires 2036-09-01 F2 · derivative.exercise_date: The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:21 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 134,513 | $0.00 | $0.00 |
DisclosureSEC source: 0002148701-26-000008 · form4-09012026_090941.xml · nonDerivative · entry 1 Abu-Absi Susan · CIK 0002148701 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,513 F1 · shares: These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.